Phase II
AstraZeneca and Daiichi Sankyo presented positive data from their Phase II single-arm DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201) in HER2-positive metastatic breast cancer patients who received two or more previous HER-2 targeted regimens.
Companies from across the globe provide updates to their business and pipelines.
Data on 52 patients in the 145-patient clinical trial highlight ADCT-402 (loncastuximab tesirine) continues to demonstrate anti-tumor activity and manageable toxicity in heavily pretreated patients
BioSpace put together a list of the top 10 indications being researched in the area by pharma companies, academic institutions and other organizations.
As the 61st American Society of Hematology Annual Meeting wrapped up in Orlando, Florida, there were hundreds of studies and results presented. Here’s a look at some.
Under a Technology License Agreement with the Houston Methodist Research Institute, Contract Developer and Manufacturer VGXI Achieves Key Milestones with Establishment of Pilot Production Capabilities for RNA-Based Medicines.
The primary efficacy endpoint was change in best corrected visual acuity (BCVA) at 16 weeks compared to sham (placebo) treatment.
When Bristol-Myers Squibb acquired Celgene this year for $74 billion, one of the drugs it picked up was a CAR-T therapy, lisocabtagene maraleucel (liso-cel).
It was, as usual, a pretty busy week in clinical trial news. Here’s a look.
Over the course of the past year, Novartis has seen significant success with the approval of five drugs that have blockbuster potential and the company sees an additional 25 potential blockbuster drugs in its pipeline.
PRESS RELEASES